Nicox (Euronext Growth: ALCOX)

Last close As at 20/12/2024

0.28

0.01 (2.60%)

Market capitalisation

EUR19m

NicOx is a French pharmaceutical company seeking to become an ophthalmology specialist. Its core nitric oxide-donating platform creates new versions of existing drugs. BOL-303259-X is entering Phase III trials for glaucoma in partnership with Bausch+Lomb.

Latest Insights

View More

Healthcare | Flash note

Nicox — Animal data show favourable profile vs Lumigan

Healthcare | Update

Nicox — Q323 update confirms trajectory for NCX-470

Healthcare | Flash note

Nicox — Denali trial remains on track for 2025 readout

Healthcare | Flash note

Nicox — Nicox provides NCX-470 sales potential estimates

nicox01

Research

Flash note

Healthcare

Nicox — Nicox provides NCX-470 sales potential estimates

Update

Healthcare

Nicox — Revisiting commercial assumptions

Flash note

Healthcare

Nicox — Chinese partner Ocumension files Zerviate NDA

Update

Healthcare

Nicox — Continuing NCX-470 development strategy

edison tv

Healthcare

Nicox – executive interview

Flash note

Healthcare

Nicox — Q4 highlights confirm continued Vyzulta growth

Update

Healthcare

Nicox — €10m financing boosts cash runway into Q224

Update

Healthcare

Nicox — Revising NCX-470 forecasts after Mont Blanc

Thematics

thematic

Healthcare

Healthcare-focused trusts: A sector on the mend

thematic

Healthcare

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

volition01

thematic

Healthcare

VolitionRx – Decoding the DNA of cancer 

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free